AHP VERDIA (TASOSARTAN) NDA FILED IN DECEMBER; NAPRELAN POSTS $51.7 MIL. SALES IN U.S.; LODINE SYSTEM FROM ELAN COMING; THREE HRT PATCHES IN PHASE III
Executive Summary
American Home Products could have a new angiotensin II antagonist on the market in the U.S. for the beginning of 1998 to revitalize its U.S. cardiovascular business. The NDA for Verdia (tasosartan) was submitted to FDA in December, projecting a possible FDA action by the end of the current calendar year.